Pacira Pharmaceuticals Inc (PCRX) EPS Estimated At $-0.22

October 13, 2017 - By Migdalia James

 Pacira Pharmaceuticals Inc (PCRX) EPS Estimated At $ 0.22
Investors sentiment increased to 1.62 in 2017 Q2. Its up 0.45, from 1.17 in 2017Q1. It is positive, as 23 investors sold Pacira Pharmaceuticals Inc shares while 45 reduced holdings. 37 funds opened positions while 73 raised stakes. 39.35 million shares or 1.09% less from 39.78 million shares in 2017Q1 were reported.
Great Point Ltd Limited Liability Company stated it has 300,000 shares. Great West Life Assurance Can invested in 0% or 3,835 shares. Healthcor Management Ltd Partnership stated it has 3.09% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Dekabank Deutsche Girozentrale has invested 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Jefferies Grp Inc Ltd Liability Corp holds 0.01% or 24,294 shares. Parametric Port Associates Ltd Liability Co accumulated 111,193 shares or 0.01% of the stock. Barclays Public Ltd Com holds 0% or 5,221 shares in its portfolio. Tygh Inc accumulated 58,710 shares or 0.63% of the stock. Voya Mgmt Llc invested 0.05% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Evercore Wealth Management Limited Liability Company has invested 0.01% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Legal And General Gp Pcl stated it has 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Rock Springs Cap Management Limited Partnership invested in 1.04 million shares. Envestnet Asset Mgmt invested 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Citigroup owns 96,781 shares. Amalgamated Commercial Bank invested in 0.01% or 5,030 shares.

Since May 15, 2017, it had 0 insider buys, and 9 sales for $2.59 million activity. Williams Kristen Marie sold $81,314 worth of stock or 1,877 shares. Shares for $1.02M were sold by Scibetta James S. Jones James B had sold 767 shares worth $33,227 on Monday, June 5. $186,757 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by STACK DAVID M. $33,271 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were sold by Braunstein Scott.

Wall Street await Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to release earnings on November, 1. After posting $-0.29 EPS for the previous quarter, Pacira Pharmaceuticals Inc’s analysts now forecast -24.14 % EPS growth. About 574,106 shares traded. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since October 13, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage

Among 19 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Pacira Pharmaceuticals had 59 analyst reports since July 28, 2015 according to SRatingsIntel. As per Monday, August 21, the company rating was upgraded by Janney Capital. The rating was maintained by Jefferies with “Buy” on Monday, September 26. The stock has “Hold” rating by Cowen & Co on Friday, July 14. Piper Jaffray maintained the shares of PCRX in report on Wednesday, August 2 with “Buy” rating. As per Monday, August 3, the company rating was upgraded by Bank of America. On Friday, September 29 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock has “Buy” rating by Mizuho on Wednesday, August 2. The firm has “Buy” rating given on Tuesday, July 25 by H.C. Wainwright. The rating was downgraded by Brean Capital to “Hold” on Friday, July 1. The firm has “Buy” rating given on Tuesday, April 19 by Mizuho.

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.37 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

More notable recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: Seekingalpha.com which released: “Pacira Pharmaceuticals (PCRX) Q1 2017 Results – Earnings Call Transcript” on May 04, 2017, also Globenewswire.com with their article: “Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission …” published on September 27, 2017, Globenewswire.com published: “Pacira Pharmaceuticals Appoints Mark I. Froimson, MD, to Board of Directors” on June 15, 2017. More interesting news about Pacira Pharmaceuticals Inc (NASDAQ:PCRX) were released by: Seekingalpha.com and their article: “Pacira Pharmaceuticals (PCRX) Q2 2017 Results – Earnings Call Transcript” published on August 02, 2017 as well as Seekingalpha.com‘s news article titled: “Pacira’s EXPAREL Reducing Opioid Consumption” with publication date: September 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.